Next Article in Journal
Crystallographic Studies Evidencing the High Energy Tolerance to Disrupting the Interface Disulfide Bond of Thioredoxin 1 from White Leg Shrimp Litopenaeus vannamei
Next Article in Special Issue
Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use
Previous Article in Journal
Obtaining Ready-to-Eat Blue Corn Expanded Snacks with Anthocyanins Using an Extrusion Process and Response Surface Methodology
Article Menu

Export Article

Open AccessReview
Molecules 2014, 19(12), 21085-21112;

HIV-1 and Its Resistance to Peptidic Carbohydrate-Binding Agents (CBAs): An Overview

Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10. Leuven B-3000, Belgium
Author to whom correspondence should be addressed.
Received: 22 October 2014 / Revised: 4 December 2014 / Accepted: 8 December 2014 / Published: 15 December 2014
(This article belongs to the Special Issue Protein-Carbohydrate Interactions, and Beyond)
Full-Text   |   PDF [2830 KB, uploaded 15 December 2014]   |  


The glycoproteins on the surfaces of enveloped viruses, such as HIV, can be considered as a unique target for antiviral therapy. Different carbohydrate-binding agents (CBAs) target specific glycans present on viral glycoproteins of enveloped viruses. It has been shown that long-term CBA pressure in vitro can result in mutant HIV-1 isolates with several N-linked glycan deletions on gp120. These studies demonstrated that mainly high-mannose type glycans are deleted. However, interestingly, N241, N262 and N356 on gp120 have never been found to be affected after prolonged CBA exposure. Here, we review the mutation and (cross)-resistance profiles of eleven specific generated CBA-resistant HIV-1 strains. We observed that the broad-neutralizing anti-carbohydrate binding mAb 2G12 became completely inactive against all the generated CBA-resistant HIV-1 clade B isolates. In addition, all of the CBAs discussed in this review, with the exception of NICTABA, interfered with the binding of 2G12 mAb to gp120 expressed on HIV-1-infected T cells. The cross-resistance profiles of mutant HIV-1 strains are varying from increased susceptibility to very high resistance levels, even among different classes of CBAs with dissimilar sugar specificities or binding moieties [e.g., α(1,3), α(1,2), α(1,6)]. Recent studies demonstrated promising results in non-topical formulations (e.g., intranasally or subcutaneously), highlighting their potential for prevention (microbicides) and antiviral therapy. View Full-Text
Keywords: HIV; carbohydrate-binding agents; resistance; therapy; microbicide; N-linked glycans; deletions HIV; carbohydrate-binding agents; resistance; therapy; microbicide; N-linked glycans; deletions

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Férir, G.; Gordts, S.C.; Schols, D. HIV-1 and Its Resistance to Peptidic Carbohydrate-Binding Agents (CBAs): An Overview. Molecules 2014, 19, 21085-21112.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top